

From LAL to rFC assays

A more sustainable future for endotoxin testing

Author: Allen L. Burgenson, Global Subject Matter
Expert, Testing Solutions Lonza Walkersville, Inc.,
Walkersville, MD, USA

Bacterial endotoxins are pyrogenic lipopolysaccharides found in the outer cell membrane of Gram-negative bacteria. Ubiquitous in the environment, endotoxins can easily enter the patient's bloodstream accidentally via contaminated parenteral drugs or implantable medical tools such as intravenous infusion devices.

From LAL to rFC Assays

An Introduction to Bacterial Endotoxin Testing


An immune response can result in debilitating symptoms such as fever and vomiting, and can even be fatal. As such, bacterial endotoxin testing (BET) is an essential safety requirement in the pharmaceutical and biomedical industries.

The *Tachypleus* and *Limulus* Amebocyte Lysate (TAL/LAL) assays are currently the most commonly used tests for detecting bacterial endotoxins. These assays are produced using whole cell lysates of specialized immune cells (amebocytes) found in the blood of various species of horseshoe crabs. Specifically, the LAL assay uses amebocytes from the *Limulus polyphemus* species, which inhabits eastern coastal areas of North America, whereas the TAL assay uses amebocytes from the *Tachypleus gigas* and *T. tridentatus* species found in various regions in Asia.

Amebocytes form part of the horseshoe crab's innate immune defense system and their granules naturally form a clot when they encounter endotoxins, providing a powerful reagent for detecting clinically harmful levels. Indeed, after its introduction over 50 years ago¹, the LAL assay has become universally regarded as a highly sensitive and specific method that reliably detects endotoxin contamination. The applications of LAL are also extensive. For example, it has been used to detect endotoxins in pharmaceutical preparations, on-site tests of short-lived radioisotopes, food quality testing, and environmental monitoring.

The importance of horseshoe crab conservation

Despite the value of the LAL assay, there are growing concerns about the effects of the LAL/TAL industry on global populations of horseshoe crabs. These "living fossils" represent a remarkable feat of evolutionary resilience, having survived on Earth for an astounding 450 million years. They also play a vital role in the wider ecosystem. For example, in the Delaware Bay Estuary on the eastern coast of the United States, tens of thousands of shorebirds, such as the red knot (*Calidris canutus*), rely on surplus Atlantic horseshoe crab eggs for critical energy reserves to make long migratory flights.



Atlantic horseshoe crabs have long been harvested as bait for commercial American eel and conch fisheries. Significant efforts have been made to prevent these activities from having a detrimental impact on the Atlantic horseshoe crab populations, and to protect the supply of LAL. For example, since 1998, interstate harvesting quotas have been enforced by the Atlantic States Marine Fisheries Commission (ASMFC). Moreover, the non-profit Ecological Research and Development Group (ERDG) has developed a variety of horseshoe crab conservation initiatives such as the introduction of bait bags to reduce the number of crabs used as bait,

in addition to the "Just flip 'em!" Program, an initiative that encourages beachgoers to "flip" stranded horseshoe crabs during the spawning season. In 2019, the stock status of Atlantic horseshoe crabs was found to be either neutral or good in most eastern coastal areas of the USA.²

However, the situation is different in Asia, where no national regulations on harvesting or bleeding practices exist. Although some regional regulations are in place (such as along the coast of the southern region of Guangxi in China), their enforcement across typically huge geographical areas is extremely challenging. Consequently, two of the three Asian horseshoe crab species are routinely bled to death in the production of TAL and then sold for human consumption. Along with unregulated commercial fishing, these unsustainable practices are causing population decline in some areas. For example, in China, horseshoe crabs were once commonly found from the mouth of the Yangtze to the Guangxi coast. But none have been seen along the coast of Zhejiang province for over a decade, and there are now only occasional sightings in Fujian, Guangdong and Guangxi.³

The drive towards a different endotoxin testing approach

The pharmaceutical and medical device industries are moving toward non-animal assays as well as sustainable solutions that are not reliant on a single source, or those that may be manufactured anywhere in the world. Recombinant assays deliver on all of these customer needs. The raw materials use recombinant DNA technology, and are grown in cell culture, similar to the process used in making many of today's recombinant therapeutics.

Additionally, the emergence of personalized medicine, such as cell or gene therapies, will mean each product will need to be tested individually, requiring more frequent endotoxin testing and subsequently placing even greater demand on lysate-based tests. As such, the industry has long recognized the need to change its approach and widely adopt more sustainable endotoxin testing methods that do not affect horseshoe crabs or the wider ecosystem in which they play a key role.

Although such change can take time and require significant investment in the short term, these initial costs can be far surpassed by the long-term benefits. One illustrative example is the replacement of the traditional qualitative Rabbit Pyrogen Test (RPT) by the LAL assay for many pharmaceutical and biomedical products. This change ultimately benefited the industry by providing an ethically more acceptable assay with higher sensitivity that can be run with relative ease and speed. Moreover, the LAL assay enables quantitative measurements of endotoxin to demonstrate the allowable limit for license specifications (for example, large volume parenterals must not contain greater than 5 IU endotoxin per kg body mass).⁴

This demonstrates how widespread change in the industry's approach to endotoxin testing is not only achievable but can also be extremely valuable.

The sustainable recombinant Factor C (rFC) assay

One sustainable endotoxin testing method is the recombinant Factor C (rFC) assay. This is the recombinant version of Factor C, an element found in the amoebocyte cells of horseshoe crabs. Both the natural and recombinant versions of Factor C activate the clotting cascade when triggered by endotoxins (Figure 1) to detect endotoxin presence and provide a measurement of the amount.




Figure 1. Natural Factor C initiates a clotting cascade measured using turbidimetric and chromogenic assays. Lonza's synthetic PyroGene® Recombinant Factor C Assay triggers a similar reaction, but the output is measured using a simpler fluorogenic assay that does not rely on an amplification cascade.

Lonza first recognized the need for a sustainable endotoxin testing method over 20 years ago, when the company had the forethought to start developing a recombinant solution: the PyroGene® Recombinant Factor C Assay. This is an end-point fluorescence test that is biochemically and practically equivalent to LAL, which uses rFC to cleave a fluorogenic substrate and subsequently reveal a measurable fluorescent signal (Figure 2).




Figure 2. The PyroGene® Recombinant Factor C Assay works through the same initial binding step as LAL BET assays, except that it only requires the binding of one protein to produce a measurable fluorescent signal.

Endorsed by the 2012 FDA guideline and the European Pharmacopoeia (Ph. Eur. 2.6.32), the rFC assay has been shown to perform comparable to TAL/LAL-based approaches.⁵ As well as improved assay performance, it also offers several other advantages. For example, it protects against TAL shortage and the potential impact of the growing demand for LAL. Also, as it is not reliant on horseshoe crab blood, it helps meet ethical and regulatory initiatives to minimize animal use in testing (such as the 3Rs principle to Replace-Reduce-Refine).

Additionally, the recombinant PyroGene® Assay provides improved lot-to-lot consistency compared to the LAL test, which exhibits some variability between different batches of the same product when obtained from different crabs and at different collection times. Other key benefits of this recombinant method are that it is easy to use and offers enhanced endotoxin specificity (with a sensitivity range of 0.005 – 5 EU/mL) and statistically more robust spike recovery.

Recent regulatory developments regarding recombinant Factor C

Despite the benefits of rFC, the assay has historically been listed as an “alternative method” in Pharmacopoeial guidelines. This meant that its use in BET required additional validation steps, which deterred some manufacturers from using it. However, in September 2018, Eli Lilly’s new migraine prevention drug, Emgality® (galcanezumab), was the first drug approved by the US FDA that uses the rFC assay instead of traditional LAL-based methods for endotoxin detection in clearance tests.⁶

Following this, in 2021, the rFC test was recognized as a compendial test in the European Pharmacopoeia. Most recently, the United States Pharmacopoeia Expert Committee has approved the addition of chapter <86> “BACTERIAL ENDOTOXINS TEST USING RECOMBINANT REAGENTS” to the United States Pharmacopoeia–National Formulary (USP–NF). This chapter will be published in November 2024 for early adoption and will become official in May 2025. While other world pharmacopoeia still recognize the rFC method as an alternative test to the LAL test^{8,9}, overall these recent changes suggest that rFC is becoming a more accepted method for bacterial endotoxin testing and could lead to its wider adoption in the pharmaceutical and biomedical industry.



The PyroGene® Recombinant Factor C Assay utilizes liquid reagents that eliminate the need for reconstitution and reduces waste of reagents.

A changing tide in bacterial endotoxin testing

There is clearly a growing recognition of the importance of a sustainable approach to bacterial endotoxin testing. Although there is every indication that the rFC assay is gaining momentum, the time and investment required for its widespread adoption means that it is unlikely to replace LAL-based tests completely for many years to come.

The generation of further evidence-based and accurate proof-of-principle data is vital to continue the drive away from animal-derived lysate-based tests and adopt more sustainable testing practices. Indeed, as more companies like Eli Lilly take the lead and obtain regulatory approval for more drugs that use rFC in clearance tests, other organizations are likely to follow suit and gain the many benefits that a synthetic, recombinant approach offers.

A phased approach to rFC adoption

Adopting the rFC assay in a phased manner allows companies to reap the immediate benefits of using a recombinant assay with fewer disruptions to the overall endotoxin testing program. Focusing first on testing products with no or minimal regulatory impact, like in-process water and raw materials, allows companies to optimize resources and mitigate risk all while working towards their sustainability goals. For many sites, in-process water testing forms a large portion of all endotoxin tests performed and requires no up front notification to regulatory authorities prior to implementation.

Closing remarks

The pharmaceutical and biomedical industries cannot ignore the need for a sustainable approach to bacterial endotoxin testing. Amid growing concern for global horseshoe crab populations and their key role in the wider ecosystem, the need for a recombinant endotoxin test which reduces dependence on a natural resource has become paramount. Also, with the TAL supply under threat and the demand for BET increasing globally, the LAL industry is unlikely to be able to sustain this huge burden in the future. The rFC assay has emerged as a sustainable technology that is comparable to LAL and offers significant benefits such as ease of use and minimal lot-to-lot variability. In the past, the rFC assay has struggled to be accepted as anything more than an 'alternative' test in various Pharmacopeia. However, with newly approved drugs like Emgality® using the rFC assay as a clearance test, and the growing recognition of its importance by various Pharmacopeia, widespread adoption of the rFC method could be on the horizon.

References:

1. **Levin and Bang (1968)** *Clottable protein in Limulus: Its localization and kinetics of its coagulation by endotoxin*. *Thrombosis et Diathesis Haemorrhagica* 19:186
2. **Atlantic States Marine Fisheries Commission (2019)**. *2019 Horseshoe Crab Benchmark Stock Assessment and Peer Review Report*. http://www.asafc.org/uploads/file/5cd5d6f1HSCAssessment_PeerReviewReport_May2019.pdf (accessed 19 November 2019)
3. **Jianshan, Z (2019)**. *After 450 Million Years, the Chinese Horseshoe Crab is Now Endangered*. <https://chinadialogueocean.net/10410-chinese-horseshoe-crab-endangered> (accessed 19 November 2019)
4. **World Health Organization (2014)**. *Implementation of the Revised General Monograph on Parenteral Preparations in The International Pharmacopeia: Limits for the Test for Bacterial Endotoxins (3.4)*. (accessed 19 November 2019)
5. **Kikuchi et al. (2017)** *Collaborative Study on the Bacterial Endotoxins Test Using Recombinant Factor C-based Procedure for Detection of Lipopolysaccharides*. *Pharmaceutical and Medical Device Regulatory Science* 48(4):252
6. **Parenteral Drug Association (2018)**. *FDA Approves Lilly's Emgality Using Lonza's Factor C Assay*. <https://news.pda.org/article/105792/fda-approves-lillys-emgality-using-lonzas-factor-c-assay> (accessed 28 November 2019)
7. **Council of Europe (2019)**. *New general chapter on test for bacterial endotoxins using recombinant factor C. Give your feedback*. <https://www.edqm.eu/en/-/new-general-chapter-on-test-for-bacterial-endotoxins-using-recombinant-factor-c.-give-your-feedback.-2> (accessed 28 November 2019)
8. **Pharmaceutical Medical Devices Agency (2019)**. *Bacterial Endotoxins Test and alternative methods using recombinant protein-reagents for endotoxin assay*. <https://www.pmda.go.jp/files/000231653.pdf> (downloaded 28 November 2019)
9. **Chinese Pharmacopeia (2018)**. *Adoption of the ICH Q4 Pharmacopoeial Test Method Workshop was held in Beijing*. <https://www.pharmtech.com/view/harmonization-efforts-pharmacopoeias-and-regulatory-agencies-1> (accessed 28 November 2019)

Contact Us

North America

Customer Service: + 1 800 638 8174 (toll free)
order.us@lonza.com
Scientific Support: + 1 800 521 0390 (toll free)
scientific.support@lonza.com

Europe

Customer Service: + 32 87 321 611
via PDF to: automated.lbs@lonza.com
Scientific Support: + 49 221 99199 400
scientific.support.eu@lonza.com

International

Contact your local Lonza Distributor
Customer Service: + 1 301 898 7025
scientific.support@lonza.com

Lonza Walkersville, Inc. – Walkersville, MD 21793

Learn more.



All trademarks belong to Lonza or its affiliates, and are registered in the USA, EU and/or CH, or belong to their respective third-party owners and are only being used for informational purposes. All third-party copyrights have been reproduced with permission from their owners. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with all applicable laws, including all environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights. The user bears the sole responsibility for determining the existence of any such third-party rights, as well as obtaining any necessary licenses and approvals. For more details: www.lonza.com/legal. ©2025 Lonza. All rights reserved.

RT-SP022 06/25

bioscience.lonza.com
lonza.com/pyrogene